ReviewAmerican journal of translational research2025
Inflammatory mechanisms in diabetic retinopathy: pathogenic roles and therapeutic perspectives.
Review in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diabetic retinopathy and the risk of all-cause dementia, Alzheimer's disease, and vascular dementia: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Bumetanide‑blocked SLC12A2 exerts a protective effect in experimental diabetic retinopathy.International journal of molecular medicine · 2026Article
- Mechanistic insights into the role of salicin in mitigating oxidative and inflammatory pathways of diabetic complications.Molecular biology reports · 2026Review
- Paired Tear Fluid - Plasma Inflammatory Profiling Identifies Compartment-Specific Biomarkers for Diabetic Retinopathy and Diabetic Macular Edema.Journal of inflammation research · 2026Article
- Exerkines in diabetic retinopathy: from mechanisms to therapeutic prospects.Frontiers in endocrinology · 2026Review
- Development and validation of a prediction model for microvascular complications of type 2 diabetes based on inflammation-metabolism composite indicators.Frontiers in endocrinology · 2026Article
- Cathepsin H drives hypoxia-associated inflammatory and angiogenic programs in diabetic retinopathy and represents a potential therapeutic target.International journal of biological sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR), a leading cause of global vision impairment, represents one of the most prevalent microvascular complications of diabetes. Numerous studies have confirmed that inflammatory processes and aberrant angiogenesis constitute pivotal pathological mechanisms in DR. Elevated levels of pro-inflammatory mediators - including cytokines, chemokines, and adhesion molecules - have been consistently detected in the serum, ocular fluids (aqueous humor and vitreous), retinal tissue, and tear film of DR patients, forming an intricate molecular network that drives disease progression. Importantly, modulation of these inflammatory components demonstrates potential to attenuate both vascular abnormalities and neurodegeneration in DR. This mechanistic understanding positions inflammation as a promising therapeutic target, highlighting the need for further investigation into anti-inflammatory strategies for DR management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.